$APRE
Aprea Therapeutics, Inc.

2022 Q3 Form 10-Q Financial Statement

#000155837022013512 Filed on August 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.083M $15.63M $3.985M
YoY Change -9.73% 367.61% 16.19%
% of Gross Profit
Research & Development $1.118M $6.812M $4.090M
YoY Change -81.42% 2.36% -39.54%
% of Gross Profit
Depreciation & Amortization $120.00 $3.730K $2.942K
YoY Change -96.18% -44.49% -18.0%
% of Gross Profit
Operating Expenses $4.200M $98.47M $8.075M
YoY Change -55.46% 884.89% -20.75%
Operating Profit -$4.200M -$98.47M
YoY Change
Interest Expense $151.1K $52.49K $1.971K
YoY Change -458048.48% -9027.04% -286.47%
% of Operating Profit
Other Income/Expense, Net $175.5K $207.1K $138.2K
YoY Change -899.8% -181.7% -73.47%
Pretax Income -$4.025M -$98.26M -$7.937M
YoY Change -57.42% 858.52% -17.92%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.025M -$98.26M -$7.937M
YoY Change -57.42% 858.52% -17.91%
Net Earnings / Revenue
Basic Earnings Per Share -$0.12 -$4.34 -$0.36
Diluted Earnings Per Share -$0.12 -$4.34 -$0.36
COMMON SHARES
Basic Shares Outstanding 23.40M 22.66M 21.90M
Diluted Shares Outstanding 34.66M 22.66M 21.90M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $33.11M $39.06M $47.65M
YoY Change -46.1% -44.04% -38.59%
Cash & Equivalents $33.11M $39.06M $47.65M
Short-Term Investments
Other Short-Term Assets $361.2K $1.401M $2.393M
YoY Change -51.9% -6.26% -4.28%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $33.47M $40.46M $50.04M
YoY Change -46.17% -43.25% -37.52%
LONG-TERM ASSETS
Property, Plant & Equipment $12.24K $20.26K $20.59K
YoY Change -55.21% -34.56% -93.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $29.35K $29.36K $29.37K
YoY Change -0.08% -0.07%
Total Long-Term Assets $148.1K $220.6K $292.1K
YoY Change -51.52% -12.27% -2.62%
TOTAL ASSETS
Total Short-Term Assets $33.47M $40.46M $50.04M
Total Long-Term Assets $148.1K $220.6K $292.1K
Total Assets $33.62M $40.68M $50.34M
YoY Change -46.19% -43.14% -37.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.136M $3.990M $1.988M
YoY Change -55.42% 68.96% -43.2%
Accrued Expenses $2.862M $3.694M $4.732M
YoY Change -55.91% -55.15% -39.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.998M $7.684M $6.720M
YoY Change -55.77% -27.49% -40.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $28.06K
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00 $28.06K
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.998M $7.684M $6.720M
Total Long-Term Liabilities $0.00 $0.00 $28.06K
Total Liabilities $3.998M $7.684M $6.748M
YoY Change -55.92% -27.49% -39.75%
SHAREHOLDERS EQUITY
Retained Earnings -$291.4M -$287.3M -$189.1M
YoY Change 68.04% 75.28%
Common Stock $52.24K $23.40K $21.97K
YoY Change 144.56% 10.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $26.63M -$35.78M $43.59M
YoY Change
Total Liabilities & Shareholders Equity $33.62M $40.68M $50.34M
YoY Change -46.19% -43.14% -37.39%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$4.025M -$98.26M -$7.937M
YoY Change -57.42% 858.52% -17.91%
Depreciation, Depletion And Amortization $120.00 $3.730K $2.942K
YoY Change -96.18% -44.49% -18.0%
Cash From Operating Activities -$6.593M -$8.903M -$5.495M
YoY Change -19.93% 14.81% -52.31%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 584.5K 0.000 0.000
YoY Change 572.01%
NET CHANGE
Cash From Operating Activities -6.593M -8.903M -5.495M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 584.5K 0.000 0.000
Net Change In Cash -6.008M -8.903M -5.495M
YoY Change -26.25% 14.81% -52.31%
FREE CASH FLOW
Cash From Operating Activities -$6.593M -$8.903M -$5.495M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$6.593M -$8.903M -$5.495M
YoY Change -19.93% 14.81% -52.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.34
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.77
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.94
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22661835
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21186827
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22283783
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21186827
dei Entity Central Index Key
EntityCentralIndexKey
0001781983
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
us-gaap Lease Practical Expedients Package
LeasePracticalExpedientsPackage
true
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23401846
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21859413
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39069
dei Entity Registrant Name
EntityRegistrantName
Aprea Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-2246769
dei Entity Address Address Line1
EntityAddressAddressLine1
535 Boylston Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02116
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
463-9385
dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
APRE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23401846
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39062415
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53076052
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1400837
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3508358
CY2022Q2 us-gaap Assets Current
AssetsCurrent
40463252
CY2021Q4 us-gaap Assets Current
AssetsCurrent
56584410
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20258
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23870
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
170967
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
185811
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
29359
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
29372
CY2022Q2 us-gaap Assets
Assets
40683836
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
189116
CY2021Q4 us-gaap Assets
Assets
56823463
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3989794
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1773032
CY2022Q2 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
3505287
CY2021Q4 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
5352996
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-98258474
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-10251013
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
190471
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7684197
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7316499
CY2022Q2 us-gaap Liabilities
Liabilities
7684197
CY2021Q4 us-gaap Liabilities
Liabilities
7316499
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23401846
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21859413
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
23401
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
21859
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
261795121
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
240978439
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10266806
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10358956
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-287329545
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-181134378
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-35777829
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
49506964
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
40683836
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
56823463
CY2022Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6811609
CY2021Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6654257
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
10901186
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
13418105
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15633738
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3343325
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19619036
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6769158
CY2022Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
76020184
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
76020184
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
98465531
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
9997582
us-gaap Operating Expenses
OperatingExpenses
106540406
us-gaap Operating Expenses
OperatingExpenses
20187263
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
52491
CY2021Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-588
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
54462
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1645
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
154566
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-252843
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
290777
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
269140
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
207057
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-253431
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
345239
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
267495
us-gaap Net Income Loss
NetIncomeLoss
-19919768
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
157655
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
193020
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
92150
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-209830
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-98100819
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10057993
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-106103017
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20129598
us-gaap Net Income Loss
NetIncomeLoss
-106195167
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.34
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.77
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.94
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22661835
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21186827
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22283783
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21186827
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
77395207
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1822562
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-402850
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-9668755
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
69146164
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1863498
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
193020
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-10251013
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
60951669
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
49506964
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2084060
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-65505
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7936693
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
43588826
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2602850
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14801615
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
157655
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-98258474
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-35777829
us-gaap Profit Loss
ProfitLoss
-106195167
us-gaap Profit Loss
ProfitLoss
-19919768
apre Research And Development In Process Noncash
ResearchAndDevelopmentInProcessNoncash
72523293
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6666
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6724
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
16885675
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
3686060
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
120795
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
129518
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
290777
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
269140
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2126847
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2533713
apre Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-107306
apre Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-135934
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1904566
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2288527
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2142301
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1756495
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14397942
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19273988
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-14397942
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-19273988
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
384305
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60148
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53076052
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89017686
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39062415
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69803846
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
123786
us-gaap Stock Issued1
StockIssued1
70107167
CY2022Q2 us-gaap Cash
Cash
39100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b>—The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses as of and during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. Significant items subject to such estimates and assumptions, are used for, but not limited to, include stock-based compensation and accounting for research and development costs.</p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11904984
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5328809
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
84900
us-gaap Operating Lease Expense
OperatingLeaseExpense
159716
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
84401
us-gaap Operating Lease Expense
OperatingLeaseExpense
176087
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
60679
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
58481
us-gaap Operating Lease Cost
OperatingLeaseCost
120795
us-gaap Operating Lease Cost
OperatingLeaseCost
116404
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
64057
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
63482
us-gaap Operating Lease Payments
OperatingLeasePayments
128113
us-gaap Operating Lease Payments
OperatingLeasePayments
126966
us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
123786
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
128163
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
63903
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
192066
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2950
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
189116
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
196674
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
247123
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1679863
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1418309
CY2022Q2 apre Research And Development Related Liabilities Current
ResearchAndDevelopmentRelatedLiabilitiesCurrent
1365298
CY2021Q4 apre Research And Development Related Liabilities Current
ResearchAndDevelopmentRelatedLiabilitiesCurrent
3504375
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
263452
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
183189
CY2022Q2 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
3505287
CY2021Q4 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
5352996
CY2022Q2 apre Stock Shares Authorized
StockSharesAuthorized
440000000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
apre Common Stock Number Of Voting Rights Per Share
CommonStockNumberOfVotingRightsPerShare
1
CY2020Q4 apre Universal Shelf Registration Maximum Amount To Be Issued
UniversalShelfRegistrationMaximumAmountToBeIssued
350000000.0
CY2020Q4 apre At Market Offering Program Maximum Amount To Be Issued
AtMarketOfferingProgramMaximumAmountToBeIssued
50000000.0
CY2020Q4 apre At Market Offering Commission Payable As Percentage Of Gross Proceeds From Sale Of Common Stock
AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock
0.03
us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
0
CY2021Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
0
us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
0
CY2022Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
0
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14801615
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16885675
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1863498
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3686060
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q2 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
100000
CY2021Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
100000
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0

Files In Submission

Name View Source Status
0001558370-22-013512-index-headers.html Edgar Link pending
0001558370-22-013512-index.html Edgar Link pending
0001558370-22-013512.txt Edgar Link pending
0001558370-22-013512-xbrl.zip Edgar Link pending
apre-20220630.xsd Edgar Link pending
apre-20220630x10q.htm Edgar Link pending
apre-20220630xex31d1.htm Edgar Link pending
apre-20220630xex31d2.htm Edgar Link pending
apre-20220630xex32d1.htm Edgar Link pending
apre-20220630xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
apre-20220630_cal.xml Edgar Link unprocessable
apre-20220630_def.xml Edgar Link unprocessable
apre-20220630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
apre-20220630_pre.xml Edgar Link unprocessable
apre-20220630x10q_htm.xml Edgar Link completed
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending